Progression-free survival, post-progression survival, and tumor response as surrogate markers for overall survival in patients with extensive small cell lung cancer
2015; Medknow; Volume: 10; Issue: 1 Linguagem: Inglês
10.4103/1817-1737.146885
ISSN1817-1737
AutoresHisao Imai, Keita Mori, Kazushige Wakuda, Akira Ono, Hiroaki Akamatsu, Takehito Shukuya, Tetsuhiko Taira, Hirotsugu Kenmotsu, Tateaki Naito, Kyoichi Kaira, Haruyasu Murakami, Masahiro Endo, Takashi Nakajima, Nobuyuki Yamamoto, Toshiaki Takahashi,
Tópico(s)Pancreatic and Hepatic Oncology Research
ResumoThe effects of first-line chemotherapy on overall survival (OS) might be confounded by subsequent therapies in patients with small cell lung cancer (SCLC). We examined whether progression-free survival (PFS), post-progression survival (PPS), and tumor response could be valid surrogate endpoints for OS after first-line chemotherapies for patients with extensive SCLC using individual-level data.
Referência(s)